ONCOLOGY: New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

Audio Journal of Oncology, December 8th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura TERRY GERNSHEIMER, University of Washington Medical Center, Seattle REFERENCE: ABSTRACT 2, ASH 2007 An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenia purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. The new drug increased platelet counts and was also well tolerated. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.

You can listen to ONCOLOGY: New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura online on Radio and Podcast. Open the player on this page to stream the available audio.

ONCOLOGY: New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura is an episode from Audio Medica News - Medical News Interviews by Audio Medica.

This episode is 00:05:00 long.

This episode was published on Dec 9, 2007.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Audio Medica News - Medical News Interviews when more episodes are available from the podcast feed.